Nephrology

Back to Results

Ronald D. Perrone, MD accepting new patients


Overview

Programs + Specialties
Training + Education Hahnemann Medical College of Philadelphia; Boston University Medical Center; Emory University Medical Center; Grady Memorial Hospital
Board Certifications Internal Medicine, Nephrology
NPI # 1265541155
Gender Male
Accepted Insurances View Accepted Insurances at Tufts MC + Floating Hospital

Locations + Directions

Tufts Medical Center
4th Floor
35 Kneeland St.
Box 391
Boston, MA 02111
Phone #: 617-636-5866
Fax #: 617-636-2369

Honors + Awards

2019, Boston Magazine Top Doctors in Nephrology
2019, Nephrology Honoree at the NKF Honors Event
2017, "Top Doctor," Boston Magazine
2017, Lillian Jean Kaplan International Prize, International Society of Nephrology
2015, "Top Doctor," Boston Magazine
2014, Physician of the Year from the Polycystic Kidney Disease Foundation
2014, Donald W. Seldin Distinguished Award from the National Kidney Foundation
2013, Top Doctor Boston Magazine
2012, "Top Doctor," Boston Magazine
2012, "Top Doctor" and in top 1% in the nation in his specialty, U.S. News & World Report
2009 Distinguished Faculty Award from TUSM
2007 Gift of Life Award - Outstanding Physician in Nephrology, National Kidney Foundation of MA, RI, NH and VT
2002, Citation for Excellence in Teaching by the Class of 2002 Tufts University School of Medicine
2001-2002 Tufts University School of Medicine Excellence in Teaching Award from the Third Year Medical Students
2000-2001, Tufts University School of Medicine Excellence in Teaching Award from the Third Year Medical Students

Publications + National Presentations

1. Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Tahbari-Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Bae KT; HALT PKD Study Group, Meyers CM. Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6:2508-15. Epub 2011 Sept 8.

2. Grantham JJ, Bennett WM, mTOR inhibitors and autosomal dominant polycystic kidney disease. N Engl J Med 2011;364:286-7; author reply 287-9.

3. Vora, N, Perrone, R, Bianchi, DW. Reproductive issues for adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Am J Kidney Dis 2008;51:307-18.

4. Alam A, Perrone, RD. Managing cyst infections in ADPKD: an old problem looking for answers. Clin J Am Soc Nephrol; 4:1154-1155, 2009.

5. Chapman, AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Oskoui FR, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Schrier RW. The Halt Polycystic Kidney Disease Trials: design and implementation. Clin J Am Soc Nephrol;5102-9,2010.

6. Alam A, Perrone RD. Management of the ESRD in patients with autosomal dominant polycystic kidney disease. Adv Chron Kid Dis;17:164-172,2010.

7. Grantham JJ, Bennett WM, Perrone RD. mTOR inhibitors and automal dominant polycystic kidney disease. N Engl J Med; 364:286-287; author reply 287-289,2011.

8. Heffernan KS, Kuvin JT, Sarnak MJ, Perrone RD, Miskulin DC, Rudym D, Chandra P, Karas RH, Menon V. Peripheral augmentation index and vascular inflammation in autosomal dominent polycystic kidney disease. Nephrol Dial Transpl; epublication February 3, 2011.

9. Oberdhan D, Cole JC, Krasa HB, Cheng R, Czerwiec FS, Hays RD, Chapman AB, Perrone RD. Development of the autosomal dominant polycystic kidney disease impact scale: a new health-related quality-of-life instrument. Am J Kidney Dis 2018; 71:225-235. Epub 2017 Nov 14; PMID:29150246.

10. Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW. ADPKD progression in patients with no apparent family history and no mutation detected by sanger sequencing. Am J Kidney Dis 2018; 71:294-296. Epub 2017 Dec 2; PMID:29203126.

11. Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE; HALT-PKD Trial Investigators. Patterns of kidney function decline in Autosomal Dominant Polycystic Kidney Disease: a post hoc analysis from the HALT-PKD Trials. Am J Kidney Dis 2018; 71:666-676. Epub 2018 Jan 3; PMID:29306517.

12. Ladin K, Pandya R, Kannam A, Loke R, Oskoui T, Perrone RD, Meyer KB, Weiner DE, Wong JB. Discussing conservative management with older patients with CKD: an interview study of nephrologists. Am J Kidney Dis 2018; 71:627-635. Epub 2018 Feb 1; PMID:29396240.

13. Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Rahbari-Oskoui FF, Steinman TI, Torres VE, The Halt-PKD Investigators. Determinants of progression in early autosomal domimant polycystic kidney disease – is it blood pressure or renin-angiotensi-aldosterone-system blockade? Curr Hypertens Rev 2018; 14:39-47. Epub 2018 Mar 21; PMID:29564978.

14. Seliger SL, Abebe KZ, Hallows KR, Miskulin DC, Perrone RD, Watnick T, Bae KT. A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease. J Am Neph 2018; 47:352-360. Epub 2018 May 18; PMID:29779024.

15. Dad T, Abebe KZ, Bae KT, Comer D, Czarnecki PG, Schrier RW, Steinman TI, Moore CG, Chapman AB, Kaya D, Tao C, Braun WE, Winklhofer FT, Brosnahan G, Hogan MC, Miskulin DC, Rahbari-Oskoui F, Flessner MF, Perrone RD. Longitudinal assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Kidney Int Rep 2018; 3:619-624. Epub 2018 Jan 6; PMID:29854969.

16. Ladin K, Pandya R, Perrone RD, Meyer KB, Kannam A, Loke R, Oskoui T, Weiner DE, Wong JB. Characterizing approaches to dialysis decision making with older adults – a qualitative study of nephrologists. Clin J Am Soc Nephrol 2018; 13:1188-1196. Epub 2018 Jul 26; PMID:30049850.

17. FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug PC, Mustafa RS, Rastogi A, Watnick R, Yu ASL, Torres VE. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol 2018; 29:2458-2470. Epub 2018 Sep 18; PMID:30228150.

18. Cho Y, Sautenet B, Gutman T, Rangan G, Craig JC, Ong AC, Chapman A, Ahn C, Coolican H, Kao JT, Gansevoort R, Perrone RD, Harris T, Torres V, Pei Y, Kerr PG, Ryan J, Johnson DW, Viecelli AK, Geneste C, Kim H, Kim Y, Oh YK, Teixeira-Pinto A, Logeman C, Howell M, Ju A, Manera KE, Tong A. Identifying patient-important outcomes in polycystic kidney disease: an international nominal group technique study. Nephrology (Carlton). 2019 Jan 20. doi: 10.1111/nep.13566. [Epub ahead of print]. PMID:30663163

19. Smith KA, Thompson AM, Baron DA, Broadbent ST, Lundstrom GH, Perrone RD. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis. 2018 Dec 29. pii: S0272-6386(18)31086-2. doi: 10.1053/j.ajkd.2018.11.001. [Epub ahead of print] PMID: 30600104

20. Cornec-Le Gall E, Chebib FT, Madsen CD, Senum SR, Heyer CM, Lanpher BC, Patterson MC, Albright RC, Yu AS, Torres VE; HALT Progression of Polycystic Kidney Disease Group Investigators, Harris PC. The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations. Am J Kidney Dis. 2018 Aug;72(2):302-308. doi: 10.1053/j.ajkd.2017.11.015. Epub 2018 Feb 1. PMID: 29395486

21.Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019 Mar 2;393(10174):919-935. doi: 10.1016/S0140-6736(18)32782-X. Epub 2019 Feb 25. Review. PMID: 30819518

22. Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O,. TEMPO 3:4 Investigators. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019 Mar 9. pii: S0085-2538(19)30041-9. doi: 10.1016/j.kint.2018.11.044. [Epub ahead of print]

View all publications >

Professional Memberships

Member, American Society of Nephrology
Member, International Society of Nephrology
Fellow, National Kidney Foundation
Fellow, American Society of Nephrology

News, Media + Videos

Claudia and her mother both suffer from PKD

FDA approval of kidney drug "a game changer"

Learn more about the clinical trials
Kidney

Tolvaptan has been FDA approved as the first-ever disease modifying drug for polycystic kidney disease

Learn more about this 'revolutionary' drug
Boston Magazine 'Top Doctor' Award 2015

Boston magazine honors 2015 “Top Doctors” at Tufts Medical Center and Floating Hospital for Children.

2015 Boston magazine Top Doctors
Boston Magazine 'Top Doctor' Award 2014

Boston magazine honors 2014 “Top Doctors” at Tufts Medical Center and Floating Hospital for Children.

2014 Boston magazine Top Doctors
Boston Magazine 'Top Doctor' Award 2017

Boston Magazine honors 2017 “Top Doctors” at Tufts Medical Center and Floating Hospital for Children.

2017 Boston Magazine Top Doctors
Dr. Clarissa Yang on the cover of 2019 Boston Magazine Top Doctor issue.

2019 “Top Doctors” at Tufts MC and Floating Hospital

See our Top Doctors

Interests

Clinical
Dr. Perrone’s patient care interests are in polycystic kidney disease, general nephrology, acid-base disorders, hypertension, and kidney transplantation medicine. He is the Director of the Polycystic Kidney Disease Center.

Research
Dr. Perrone’s research interests are largely focused in the area of polycystic kidney disease, including slowing progression and determining the natural history of the extrarenal complications. In prior studies, he addressed the mortality of extrarenal complications of polycystic kidney disease after kidney failure treated by dialysis. He will continue this work in collaboration with Drs. Alan Collins and Blanche Chavers of the United States Renal Data System.

Dr. Perrone also is the Principal Investigator of the Boston Patient Care Center of an NIH-funded multi-center clinical trial (HALT Progression in PKD, part of the Polycystic Kidney Disease Clinical Trials Network). This study uses angiotensin converting enzyme inhibitors in combination with angiotensin receptor blockers to slow the progression of polycystic kidney disease and utilizes the unique endpoint of kidney volume growth as assessed using magnetic resonance imaging. Tufts Medical Center is one of the four national HALT-PKD Study centers that will conduct this 6-year, $25 million study sponsored by the NIH. Drs. Perrone (the PI) and Miskulin direct the study that started in the winter of 2006.

Dr. Perrone is the Tufts Medical Center Principal Investigator of the TEMPO 3/4 study. TEMPO 3/4 is a global trial that is addressing the efficacy of the vasopressin-receptor antagonist tolvaptan to slow progression of polycystic kidney disease. The unique endpoint of kidney volume growth will be assessed using magnetic resonance imaging. Tufts Medical Center is one of 100 international TEMPO 3/4 Study centers.

National/International Presentations

4//2016, “Update on the Management of ADPKD in 2016 and Beyond”, Spring Clinical Meetings, National Kidney Foundation, Boston, MA

5/19/2016, “Management of Hypertension in ADPKD”, Symposium on Hypertension, Klinik Hirslanden, Zurich, Switzerland

6/2/2016, “Predicting Disease Progression and Management of ADPKD”, Keynote address at the Jared J. Grantham Symposium, Kansas University PKD Center, Kansas City, KS

6/26/2016, “Emerging Therapies in PKD”, PKD Foundation National Convention, Orlando, FL

6/26/2016, “Clinical Trials: Why YOU Should Participate”, PKD Foundation National Convention, Orlando, FL

6/26/2016, “Native Nephrectomy and Kidney Transplantation: If? When? How?”, Panelist, PKD Foundation National Convention, Orlando, FL

10/20/16, “Using CDISC Standards to Map Clinical Information in ADPKD”, Embedding Clinical Standards in Research: Development, Implementation, and Curation. By webex, sponsored by European Bioinformatics Institute, Cambridge, UK

11/17/2016, “Incorporating Patient Perspectives to Develop Patient-Centric Therapies”, American Society of Nephrology Annual Meeting, Chicago, IL.

4/23/17, “Total Kidney Volume: A Biomarker for PKD Progression,” World Congress of Nephrology, Mexico City, Mexico

6/8/17, “Total Kidney Volume: Where have we been and where are we going?,” Grantham Symposium, PKD EAB Meeting, Kansas City, MO.

6/29/17, “Lessons from CRISP, HALD PKD, TEMPO and the PKD Outcomes Consortium: TKV and other Biomarkers,” Polycystic Kidney Disease: Challenges, Differing Viewpoints and Ways Forward, sponsored by the Federation of American Societies for Experimental Biology, Big Sky, MT

9/15/2017, “Management of ADPKD in 2017”, as part of An Update on Recent Advances and Clinical Management in 2017 Toronto PKD Scientific Day, Toronto, Canada

11/4/17, “Treatment of ADPKD: Where Are We Now?” Continuing Medical Education Symposium: ADPKD – Advances in Pathogenesis and Treatment, American Society of Nephrology Annual Meeting, New Orleans, LA

11/13/17, “REPRISE (Tolvaptan) Clinical Trial Results,” Live National Webinar on behalf of the PKD Foundation.

12/2/17, “Lessons from CRISP, HALT PKD, TEMPO and the PKD Outcomes Consortium: TKV and other Biomarkers,” at Management of Polycystic Kidney Diseases from Childhood to Adulthood, University Leuven, Leuven, Belgium

7/12/2018, “FDA Biomarker Qualification and MRI Imaging Parameters qualified by FDA (PKDOC Measures)”. Renal Imaging Workshop, NIDDK, Bethesda MD

9/14/2018, “Management of ADPKD in 2018”, 2018 Toronto PKD Scientific Conference, Toronto, Canada

10/24/2018, “Emerging therapies and promising clinical trials” in early course: PKD: Translating Mechanisms into Therapy at 2018 ASN Kidney Week, San Diego, CA.

11/18/2018, “Long-term treatment of PQRAD (ADPKD) with Tolvaptan”, XLVIII Congress of the Spanish Society of Nephrology and IX Iberoamerican Congress of Nephrology, Madrid, Spain

12/6/2018, “Advances in the Management of ADPKD”, Charité – Universitätsmedizin, Berlin, Germany

12/7/2018, “Optimal management of ADPKD in patients prior to dialysis”, 31st Berliner DialyseSeminar, Berlin, Germany